Target Gene/Pathway
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z other
| No. | KEGG PATHWAY * On map, Yellow: Drug target, Red: Disease-related |
KEGG GENES * [Number of genes] |
KEGG DRUG * | DrugBank | Disease ID * [Number of diseases] |
| 1 | Adipocytokine signaling pathway |
[2] PRKAA1, PRKAA2 | D00944 | Metformin | [17] 6, 13, 46, 49, 67, 75, 77, 81, 86, 113, 158, 206, 225, 233, 265, 285, 299 |
| D04966 | |||||
| 2 | Alanine, aspartate and glutamate metabolism |
[4] ABAT, ALDH5A1, GAD1, GAD2 | D00399 | Valproic Acid | [14] 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
| 3 | Aldosterone synthesis and secretion |
[3] CACNA1G, CACNA1H, CACNA1I | D00399 | Valproic Acid | [14] 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
| 4 | AMPK signaling pathway |
[2] PRKAA1, PRKAA2 | D00944 | Metformin | [17] 6, 13, 46, 49, 67, 75, 77, 81, 86, 113, 158, 206, 225, 233, 265, 285, 299 |
| D04966 | |||||
| 5 | Apelin signaling pathway |
[2] PRKAA1, PRKAA2 | D00944 | Metformin | [17] 6, 13, 46, 49, 67, 75, 77, 81, 86, 113, 158, 206, 225, 233, 265, 285, 299 |
| D04966 | |||||
| 6 | Autophagy - animal |
[2] PRKAA1, PRKAA2 | D00944 | Metformin | [17] 6, 13, 46, 49, 67, 75, 77, 81, 86, 113, 158, 206, 225, 233, 265, 285, 299 |
| D04966 | |||||
| 7 | beta-Alanine metabolism |
[3] ABAT, GAD1, GAD2 | D00399 | Valproic Acid | [14] 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
| 8 | Butanoate metabolism |
[4] ABAT, ALDH5A1, GAD1, GAD2 | D00399 | Valproic Acid | [14] 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
| 9 | Calcium signaling pathway |
[3] CACNA1G, CACNA1H, CACNA1I | D00399 | Valproic Acid | [14] 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
| 10 | cAMP signaling pathway |
[1] GLP1R | D04121 | Exenatide | [3] 6, 193, 233 |
| 11 | Circadian entrainment |
[3] CACNA1G, CACNA1H, CACNA1I | D00399 | Valproic Acid | [14] 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
| 12 | Circadian rhythm |
[2] PRKAA1, PRKAA2 | D00944 | Metformin | [17] 6, 13, 46, 49, 67, 75, 77, 81, 86, 113, 158, 206, 225, 233, 265, 285, 299 |
| D04966 | |||||
| 13 | Cortisol synthesis and secretion |
[3] CACNA1G, CACNA1H, CACNA1I | D00399 | Valproic Acid | [14] 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
| 14 | Cushing syndrome |
[3] CACNA1G, CACNA1H, CACNA1I | D00399 | Valproic Acid | [14] 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
| 15 | Fluid shear stress and atherosclerosis |
[2] PRKAA1, PRKAA2 | D00944 | Metformin | [17] 6, 13, 46, 49, 67, 75, 77, 81, 86, 113, 158, 206, 225, 233, 265, 285, 299 |
| D04966 | |||||
| 16 | FoxO signaling pathway |
[2] PRKAA1, PRKAA2 | D00944 | Metformin | [17] 6, 13, 46, 49, 67, 75, 77, 81, 86, 113, 158, 206, 225, 233, 265, 285, 299 |
| D04966 | |||||
| 17 | GABAergic synapse |
[3] ABAT, GAD1, GAD2 | D00399 | Valproic Acid | [14] 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
| 18 | Glucagon signaling pathway |
[2] PRKAA1, PRKAA2 | D00944 | Metformin | [17] 6, 13, 46, 49, 67, 75, 77, 81, 86, 113, 158, 206, 225, 233, 265, 285, 299 |
| D04966 | |||||
| 19 | GnRH secretion |
[3] CACNA1G, CACNA1H, CACNA1I | D00399 | Valproic Acid | [14] 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
| 20 | Hypertrophic cardiomyopathy (HCM) |
[2] PRKAA1, PRKAA2 | D00944 | Metformin | [17] 6, 13, 46, 49, 67, 75, 77, 81, 86, 113, 158, 206, 225, 233, 265, 285, 299 |
| D04966 | |||||
| 21 | Insulin resistance |
[2] PRKAA1, PRKAA2 | D00944 | Metformin | [17] 6, 13, 46, 49, 67, 75, 77, 81, 86, 113, 158, 206, 225, 233, 265, 285, 299 |
| D04966 | |||||
| 22 | Insulin secretion |
[1] GLP1R | D04121 | Exenatide | [3] 6, 193, 233 |
| 23 | Insulin signaling pathway |
[2] PRKAA1, PRKAA2 | D00944 | Metformin | [17] 6, 13, 46, 49, 67, 75, 77, 81, 86, 113, 158, 206, 225, 233, 265, 285, 299 |
| D04966 | |||||
| 24 | Longevity regulating pathway |
[2] PRKAA1, PRKAA2 | D00944 | Metformin | [17] 6, 13, 46, 49, 67, 75, 77, 81, 86, 113, 158, 206, 225, 233, 265, 285, 299 |
| D04966 | |||||
| 25 | Longevity regulating pathway - multiple species |
[2] PRKAA1, PRKAA2 | D00944 | Metformin | [17] 6, 13, 46, 49, 67, 75, 77, 81, 86, 113, 158, 206, 225, 233, 265, 285, 299 |
| D04966 | |||||
| 26 | MAPK signaling pathway |
[3] CACNA1G, CACNA1H, CACNA1I | D00399 | Valproic Acid | [14] 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
| 27 | Metabolic pathways |
[4] ABAT, ALDH5A1, GAD1, GAD2 | D00399 | Valproic Acid | [14] 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
| 28 | mTOR signaling pathway |
[2] PRKAA1, PRKAA2 | D00944 | Metformin | [17] 6, 13, 46, 49, 67, 75, 77, 81, 86, 113, 158, 206, 225, 233, 265, 285, 299 |
| D04966 | |||||
| 29 | Neuroactive ligand-receptor interaction |
[1] GLP1R | D04121 | Exenatide | [3] 6, 193, 233 |
| 30 | Non-alcoholic fatty liver disease (NAFLD) |
[2] PRKAA1, PRKAA2 | D00944 | Metformin | [17] 6, 13, 46, 49, 67, 75, 77, 81, 86, 113, 158, 206, 225, 233, 265, 285, 299 |
| D04966 | |||||
| 31 | Oxytocin signaling pathway |
[2] PRKAA1, PRKAA2 | D00944 | Metformin | [17] 6, 13, 46, 49, 67, 75, 77, 81, 86, 113, 158, 206, 225, 233, 265, 285, 299 |
| D04966 | |||||
| 32 | PI3K-Akt signaling pathway |
[2] PRKAA1, PRKAA2 | D00944 | Metformin | [17] 6, 13, 46, 49, 67, 75, 77, 81, 86, 113, 158, 206, 225, 233, 265, 285, 299 |
| D04966 | |||||
| 33 | Propanoate metabolism |
[1] ABAT | D00399 | Valproic Acid | [14] 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
| 34 | Protein digestion and absorption |
[1] DPP4 | D08516 | Sitagliptin | [3] 75, 233, 299 |
| 35 | Taurine and hypotaurine metabolism |
[2] GAD1, GAD2 | D00399 | Valproic Acid | [14] 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
| 36 | Thermogenesis |
[2] PRKAA1, PRKAA2 | D00944 | Metformin | [17] 6, 13, 46, 49, 67, 75, 77, 81, 86, 113, 158, 206, 225, 233, 265, 285, 299 |
| D04966 | |||||
| 37 | Tight junction |
[2] PRKAA1, PRKAA2 | D00944 | Metformin | [17] 6, 13, 46, 49, 67, 75, 77, 81, 86, 113, 158, 206, 225, 233, 265, 285, 299 |
| D04966 | |||||
| 38 | Type I diabetes mellitus |
[2] GAD1, GAD2 | D00399 | Valproic Acid | [14] 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
| 39 | Type II diabetes mellitus |
[1] CACNA1G | D00399 | Valproic Acid | [14] 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
| 40 | Valine, leucine and isoleucine degradation |
[1] ABAT | D00399 | Valproic Acid | [14] 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |